$BDX

Garrison Michael David sold $160K of BDX

Garrison Michael David (EVP & Pres Med.Essntl&BioPharm) sold 1,100 shares of BECTON DICKINSON & CO (BDX) at $145.66 ($0.16M total) on 2026-06-24 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Garrison Michael David
Published Jun 25, 2026, 2:16 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 25, 2026, 2:28 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$BDX
Neutral
high confidence
Mentioned
$BDX
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BDXNeutralLow
01

Why it matters

The disclosed open-market sale is unlikely to change near-term fundamentals, but it can marginally influence short-term sentiment among traders monitoring insider activity.

02

Market read

Traders may note the sale as a sentiment datapoint, but the 10b5-1 structure limits actionable inference.

03

What to watch

Insider sales can be tax- or diversification-driven; without additional context (e.g., repeated sales, purchases, or changes in guidance), the signal is weak.

Relevance 3/10Novelty 3/10Timing: today’s SEC Form 4 filing (filed 2026-06-25)

Background

The article is an SEC Form 4 insider transaction disclosure for Becton Dickinson & Co.

Company-level read

Ticker impact

$BDXNeutralHigh confidence
Context

Becton Dickinson insider Garrison Michael David sold 1,100 shares at $145.66 under a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a Form 4 open-market sale with a stated pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

Minimal read-through for medical devices; this is a single-insider transaction without operational or regulatory implications.

None.

None.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • Becton Dickinson & Co

    Company whose insider transaction was disclosed via SEC Form 4.

  • Garrison Michael David

    EVP & Pres, Med. Essential & BioPharm; reported an open-market sale under a 10b5-1 plan.

Related articles

$REPLMed

This Week at FDA: Inspection reorg, acting CBER chief eyes IND reforms, and more

FDA updates cover inspection reorganization plans, proposed IND reforms for early-stage biologics research, and accelerated approval of Replimune’s Tudriqev (vusolimogene oderparepvec-wtpg) with Bristol Myers Squibb’s Opdivo for melanoma after PD-1 regimens. Other items include FDA workshops, Seegene EUA for an assay, and multiple drug/device recalls.

$BDXMed

Becton, Dickinson Boosts FY26 Adj. EPS Outlook - Update

Becton, Dickinson and Co. (BDX) reported third-quarter results and raised its FY2026 adjusted EPS outlook to $12.62 to $12.72 per share, from $12.52 to $12.72. The company kept its revenue growth view, expecting low single-digit plus growth and low single-digit constant-currency growth. Shares were about $172.00 premarket.

$BDXMedAI 8/10

BD Reports Third Quarter Fiscal 2026 Financial Results

BD (NYSE:BDX) reported fiscal 2026 third-quarter results ended June 30, 2026. Revenue rose to $5.0 billion, up 5.4% reported and 4.4% on an FX-neutral basis. GAAP and adjusted diluted EPS from continuing operations were $1.64 and $3.23. Year-to-date cash from continuing operations increased 33.3% to $2.1 billion, and free cash flow rose 44.6% to $1.7 billion. BD updated full-year guidance, expecting revenue growth toward the high end and raised the adjusted EPS midpoint.